Stocks · News reference
Brodsky & Smith Investigates Proposed Acquisition of QIAGEN N.V.
Law firm Brodsky & Smith has announced an investigation into the proposed acquisition of QIAGEN N.V. by EQT Private Equity.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck
The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.
AI in Drug Discovery Market to Reach USD 15,536.2 Million by 2033 at 25.1% CAGR | Coherent Market Insights
The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.
QIAGEN Reports Q3 2026 Financial Results and Suspends Guidance Amid EQT Offer
QIAGEN NV reported Q3 2026 revenue growth and suspended its 2026 financial guidance while a pending acquisition offer from EQT Private Equity remains outstanding.
QIAGEN Shareholders Approve Appointment of Jonathan M. Pratt to Managing Board
QIAGEN N.V. shareholders have officially approved the appointment of Jonathan M. Pratt as a Managing Director and member of the company's Managing Board.
QIAGEN N.V. Files Form 6-K for Third Quarter 2026
QIAGEN N.V. has filed its Form 6-K report with the U.S. Securities and Exchange Commission for the quarterly period ending September 30, 2026.